10-Q · May 13, 2026
Palatin Technologies reported a strong Q3 FY2026 with substantial revenue growth, generating approximately $3.92 million compared to $0 in the prior year, driven by new collaboration agreements. The company recognized…
Earnings analysis · 10-K
PTN earnings analysis
Filed September 28, 2026 · Our reading of the company's report
The latest report
Palatin generated $13.19 million of fiscal 2026 licensing revenue and reduced its net loss and operating cash burn, supported by the Boehringer Ingelheim and Altanispac transactions. Its strategy is now concentrated on…
Read full summary
Palatin generated $13.19 million of fiscal 2026 licensing revenue and reduced its net loss and operating cash burn, supported by the Boehringer Ingelheim and Altanispac transactions. Its strategy is now concentrated on early-stage MC4R obesity programs, including a weekly peptide and oral small molecule, but there is no product revenue and the core candidates remain preclinical. Despite $7.49 million of year-end cash and $18.51 million of financing inflows, management and the auditor identify substantial doubt about going-concern status, making additional financing the key near-term risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-2.96
- Operating margin
- -65.74%
- Segment
- Life science: $13,185,031 of revenue in fiscal 2026; the company manages operations as one operating segment.
What stood out
-
Licensing Revenue Replaced Zero Revenue
Revenue inflected from $0 in fiscal 2025 to $13.19 million in fiscal 2026, consisting of $9.43 million from Boehringer Ingelheim and $3.75 million from Altanispac. The company had no product revenue; all fiscal 2026 revenue came from collaboration and licensing arrangements.
-
Meaningful BI Partnership Economics
The Boehringer Ingelheim agreement provides for potential development, regulatory and commercial milestone payments of up to approximately $328 million, tiered royalties on net sales, and reimbursement of approved research costs for up to 2.5 years.
-
Focused MC4R Obesity Roadmap
Strategy is increasingly concentrated on selective MC4R agonists for rare obesity and MC4R-pathway disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The roadmap includes a once-weekly long-acting peptide agonist and a next-generation oral small-molecule agonist, with planned IND-enabling work and initiation of a Phase 1 study for the peptide program.
-
Losses and Cash Burn Improved
Net loss improved to $8.38 million in fiscal 2026 from $17.31 million in fiscal 2025, while operating cash use declined to $13.53 million from $21.31 million. The improvement was primarily associated with collaboration and license revenue, rather than product sales.
-
Financing Funded the Balance Sheet
Fiscal 2026 financing provided $18.51 million of cash, including $16.91 million from common stock and warrant sales and $1.62 million from warrant exercises. Capital spending was only $51,299, consistent with an asset-light, development-focused model.
-
Year-End Liquidity Rebuilt
Cash and cash equivalents increased to $7.49 million at June 30, 2026 from $2.56 million at June 30, 2025, and stockholders’ equity improved to $6.69 million from a $4.78 million deficiency. The improvement was funded substantially by equity and warrant financing and licensing proceeds.
What to watch
-
Going-Concern and Funding Shortfall
Management and the auditor report substantial doubt about continuing as a going concern: cash was $7.49 million at June 30, 2026 versus current liabilities of $1.77 million, and management does not expect existing cash to fund operations for at least 12 months after issuance of the financial statements. Assuming no additional funding, the company expects cash to fund currently anticipated expenses only through the second half of calendar 2026; it has no financing commitments.
-
Early-Stage MC4R Competition
The company’s principal MC4R programs are in preclinical development and have not been shown to be safe, tolerated or effective in humans. The company states that approved and investigational competitors include MC4R agonists and other mechanisms, and that its candidates must demonstrate improved tolerability, reduced off-target effects such as hyperpigmentation, and convenient dosing to differentiate.
-
Concentration in Uncertain Partnerships
Fiscal 2026 revenue was concentrated in two licensing arrangements: $9.43 million from Boehringer Ingelheim and $3.75 million from Altanispac, with the latter received as non-cash debt cancellation. Future milestone payments and royalties are uncertain, and the company does not control collaborators’ development or commercialization decisions; BI’s potential milestone pool is approximately $328 million but remains success-based.
Management's outlook
The 10-K provides no quantitative annual revenue or EPS guidance. Management expects near-term revenue to depend primarily on collaboration and licensing arrangements and states that existing cash is expected to fund currently anticipated operating expenses only through the second half of calendar 2026, assuming no additional funding.
Earlier filings 4
10-Q · February 17, 2026
Palatin Technologies reported substantial growth in revenue for Q2 FY2026, recognizing $116.036 million from collaboration and license revenue, a notable increase from $0 in the prior year period. Despite a significant…
10-Q · November 14, 2025
Palatin Technologies reported a significant revenue increase in Q1 2026, totaling $8,847,550, compared to no revenue in the same quarter of the previous year. This quarter also saw an improvement in diluted EPS, which…
10-K · September 23, 2025
Palatin Technologies has outlined an effort to develop first-in-class medicines primarily centered on the melanocortin receptor system, with a focus on obesity treatments. The fiscal year ended June 30, 2025 saw zero…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.